Evidence map›Paper›PMID 39492194›Full record

ArticleScience progress

Benzodiazepine use and incident risk of sudden cardiac arrest in patients with cardiovascular diseases.

Chunbao Mo, Shuang Wang, Xia Li, Furong Li, Cheng Jin, Bo Bai, Haolong Pei, Jing Zheng, Fengchao Liang

Abstract read
In one paragraph

Article in Science progress. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Chunbao MoSchool of Public Health and Emergency Management, School of Medicine, Southern University of Science and Technology, Shenzhen, China.
Shuang WangShenzhen Health Development Research and Data Management Center, Shenzhen, China.
Xia LiSchool of Public Health and Emergency Management, School of Medicine, Southern University of Science and Technology, Shenzhen, China.
Furong LiSchool of Public Health and Emergency Management, School of Medicine, Southern University of Science and Technology, Shenzhen, China.
Cheng JinSchool of Public Health and Emergency Management, School of Medicine, Southern University of Science and Technology, Shenzhen, China.
Bo BaiSchool of Public Health and Emergency Management, School of Medicine, Southern University of Science and Technology, Shenzhen, China.
Haolong PeiSchool of Public Health and Emergency Management, School of Medicine, Southern University of Science and Technology, Shenzhen, China.
Jing ZhengShenzhen Health Development Research and Data Management Center, Shenzhen, China.
Fengchao LiangSchool of Public Health and Emergency Management, School of Medicine, Southern University of Science and Technology, Shenzhen, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundBenzodiazepines (BZDs) are commonly prescribed as adjunctive drugs for patients with cardiovascular diseases (CVDs), particularly those who experience anxiety or insomnia. However, the relationship between the use of BZDs and incident risk of sudden cardiac arrest (SCA) has not been well investigated. In this study, we aimed to examine the association between the use of BZDs and the incident risk of SCA among patients with CVD.

methodIn this retrospective cohort study, a total of 74,715 eligible patients with new-onset CVD as a primary cause of hospitalization between July 2016 and August 2022 were included from the health information platform in Shenzhen, China. Among them, 61,761 BZD non-initiators were identified and matched to 12,954 BZD initiators by propensity score at a maximum ratio of 5:1. Propensity score-matched Cox proportional hazard models were used to estimate the hazard ratios (HRs) and 95% confidence intervals (CIs).

resultsOver a 12-month follow-up period, 29 (2.24 per 1000 person-years) and 137 (2.22 per 1000 person-years) SCA cases occurred among propensity score-matched BZD initiators and non-initiators, respectively. Patients who initiated BZD treatment were associated with a 101% increased risk of SCA incidence compared with patients without BZD treatment (adjusted HR: 2.01, 95% CI: 1.42, 2.83). Furthermore, compared with the non-use (0 defined daily dose, DDD), the adjusted HR was 1.43 (95% CI: 1.32, 1.56) for the BZD consumption of ≤1 DDD and 2.58 (95% CI: 2.37, 2.81) for the BZD consumption of >1 DDD (

conclusionThis study provides evidence that BZD initiation may be associated with an increased incident risk of SCA in patients with CVD. Our finding highlights the importance of cautious prescribing BZDs in the health management of patients with CVD.

Indexed as

BenzodiazepinesCardiovascular DiseasesDeath, Sudden, CardiacAdultAgedChinaFemaleHumansIncidenceMaleMiddle AgedPropensity ScoreProportional Hazards ModelsRetrospective StudiesRisk FactorsBenzodiazepinesBenzodiazepinescardiovascular diseasesreal-world studyretrospective cohortsudden cardiac arrest

Identifiers

PMID39492194
PMCPMC11536653

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.